Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) saw a significant increase in short interest in the month of October. As of October 13th, there was short interest totalling 2,836,313 shares, an increase of 27.4% from the September 29th total of 2,227,100 shares. Approximately 26.9% of the company’s shares are short sold. Based on an average daily volume of 797,348 shares, the short-interest ratio is currently 3.6 days.

In other news, major shareholder Michael Rapp bought 25,745 shares of the company’s stock in a transaction dated Monday, October 23rd. The stock was bought at an average cost of $9.94 per share, for a total transaction of $255,905.30. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 10.02% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Nationwide Fund Advisors purchased a new stake in Zynerba Pharmaceuticals in the 2nd quarter valued at about $110,000. The Manufacturers Life Insurance Company purchased a new stake in Zynerba Pharmaceuticals in the 2nd quarter valued at about $158,000. SG Americas Securities LLC purchased a new stake in Zynerba Pharmaceuticals in the 1st quarter valued at about $188,000. Bank of New York Mellon Corp boosted its position in Zynerba Pharmaceuticals by 5.5% in the 1st quarter. Bank of New York Mellon Corp now owns 12,165 shares of the company’s stock valued at $245,000 after buying an additional 635 shares during the period. Finally, New York State Common Retirement Fund purchased a new stake in Zynerba Pharmaceuticals in the 2nd quarter valued at about $207,000. 34.95% of the stock is owned by institutional investors.

Shares of Zynerba Pharmaceuticals (ZYNE) opened at 9.76 on Tuesday. The stock’s market capitalization is $129.39 million. Zynerba Pharmaceuticals has a one year low of $5.42 and a one year high of $25.95. The firm has a 50-day moving average of $8.41 and a 200 day moving average of $8.41.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its quarterly earnings results on Tuesday, August 1st. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.04). On average, equities research analysts predict that Zynerba Pharmaceuticals will post ($2.42) EPS for the current year.

A number of analysts have recently weighed in on ZYNE shares. Oppenheimer Holdings Inc. set a $8.00 target price on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 7th. BidaskClub upgraded shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Maxim Group set a $32.00 target price on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 1st. CIBC reiterated a “market perform” rating on shares of Zynerba Pharmaceuticals in a report on Tuesday, August 15th. Finally, Piper Jaffray Companies upgraded shares of Zynerba Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $7.00 to $16.00 in a report on Thursday, September 28th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $14.22.

ILLEGAL ACTIVITY WARNING: This report was published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.dailypolitical.com/2017/10/31/zynerba-pharmaceuticals-inc-zyne-short-interest-up-27-4-in-october.html.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.